Pneumocystis Jirovecii Pneumonia | A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy

Pneumocystis Jirovecii Pneumonia research study

What is the primary objective of this study?

In this study, we aim to investigate the incidence of the adverse reactions, the effectiveness and the gene polymorphism associated with the plasma level of sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole, sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.

Who is eligible to participate?

Inclusion Criteria: - males and females aged 20 years or older - using oral or intravenous form of sulfamethoxazole-trimethoprim Exclusion Criteria: - patients who are under 20 years of age

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Pneumocystis Jirovecii Pneumonia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Sulfamethoxazole-trimethoprim treatment

Study Status

Unknown status

Start Date: January 2014

Completed Date: December 2017


Type: Observational


Primary Outcome: High performance liquid chromatography for drug plasma concentration

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: National Taiwan University Hospital


More information:

Discuss Bactrim